Healthtronics — Investor Presentation (January 2006)
39 slides from Healthtronics's investor presentation, Jan 13, 2006
Slide 1: Presentation of HealthTronics
Exhibit 99.1 Presentation of HealthTronics January 2006 John Q. Barnidge CFO
Slide 2: Forward-looking statements
Statements in this presentation that are not strictly historical, including statements regarding plans, objective and future financial performance, are “forward-looking” statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Although
Slide 3: Business Segments/Sub-Segments
Business Segments/Sub-Segments Urology Services Lithotripsy Prostate Therapies Anatomical Pathology Medical Devices Sales Service Specialty Vehicles Medical Broadcast Homeland Security
Slide 4: Urology Services
Urology Services Lithotripsy Prostate Therapies Uropathology
Slide 5: Leading Competitive Position
Leading Competitive Position Partnering with 1/3 of Nation’s Urologists Veteran Management Team Bringing Cutting-edge Therapies to Market Successful Partnership Model Proven Execution
Slide 6: Core Objectives
Core Objectives ~ Leverage Urology Channel Trusted Advisor to our Partners Value-added Products and Services Facilitate Marketplace Consolidation Growing Revenue & Taking Share Expanding Platform Expand Margins Pricing Stability Wholesale Pricing Power Operating Efficiencies
Slide 7: Lithotripsy
Lithotripsy Cost Effective, Non-invasive, Efficacious Fractional Cost of Surgical Alternatives Market Scope 250,000 Cases per Year $2,000 per Case Revenue $500M Revenue Market Physician-driven Therapy No Alternative Therapy ~ 93 Partnerships in 47 states ~ 183 installed litho base ~ Over 750 care ve
Slide 8: Lithotripsy Partnership Economics
Lithotripsy Partnership Ecponomics
Slide 9: Prostate Therapy - BPH
Prostate Therapy - BPH Benign Prostatic Hyperplasia Non-cancerous Enlargement of the Prostate Market Scope Affects 50% of Men Over Age 60 13 Million American Men in 2004 Growth Rate From 40,000 to 360,000 Minimally Invasive Treatments $650 Million - $700 Million Market Multiple Treatment Methodologi
Slide 10: Prostate Therapy - Prostate Cancer
Prostate Therapy - Prostate Cancer Market Scope Second Most Common Cancer in American Males 230,000 New Cases per Year in the U.S. Baby Boomer Impact (approximately 40 million males) $5B market Dramatic Increase in Public Awareness Demanding Focal Therapy vs. Total Ablation Participating in the Diag
Slide 11: Prostate Therapy - Prostate Cancer Treatment Alternatives
Prostate Therapy - Prostate Cancer Treatment Alternatives
Slide 12: Uropathology Market
Uropathology Market Market is Approximately $500 Million 8,400 Private Practice Urologists Approximately 10 Prostate Biopsies / Month Each Patient = Approximately $600 Revenue 60% of Patients are Medicare Medicare Reimbursement is Excellent
Slide 13: HealthTronics Uropath Advantage - Big Lab Technology, Small Lab Service
HealthTronics Uropath Advantage - Big Lab Technology, Small Lab Service Focal Diagnosis to compliment Focal Therapies Timeliness & Accuracy – Turnaround Within 48 Hours Technology - Electronic Reporting Customer Service - Physician Oriented Pathologists
Slide 14: Development Strategy
Development Strategy Beta Users HTRN Physician Partners Beta Sites Georgia, Louisiana & Mississippi Investment 2005 CapEx $2 Million
Slide 15: Medical Device Sales & Service
Medical Device Sales & Service
Slide 16: Devices
Devices Lithotripters Market Scope: Total US Installed Base of 650 Units Average Selling Price of $390,000 35% of US Market is Spark Gap Technology US HTRN Manufactured Installed Base of 220 Units Opportunities: Dual Branding Strategy to Expand Spark Gap Market New Model with Multi-Functional Capabi
Slide 17: HTRN New Urology Imaging System
HTRN New Urology Imaging System UroVantage Image
Slide 18: Devices
Devices Urology Imaging System Market Scope: Total US Installed Base of 4,500 Units 200 - 250 Units Purchased in US Annually at $300,000 ASP Urologist Influential in Equipment Decision Market Moving Toward Multi-Specialty Surgical Units Opportunities: UroVantage launched in 2Q 2005 MultiVantage laun
Slide 19: Devices
Devices Other Products Patient Management Tables: US Installed Base of 4000 Units, HTRN 450 Units Installed Comprehensive Dealer Network, OEM Supplier PSA Testing: 6 Million PSA Tests Performed Annually, $200 Million Market In-Office Testing Approved and now Reimbursed by All Payors Signed Marketing
Slide 20: Service Engineering
Service Engineering Installed Base/Network: Currently Service 38% of US Lithotripter Installed Base 180 of 250 Total HTRN Service Base is Within Partnerships 36 Field Engineers Trained in Lithotripsy and X-Ray 530 Units Generating Consumable Revenue Opportunities: ISO Certification in Atlanta Manufa
Slide 21: Specialty Vehicle Manufacturing
Specialty Vehicle Manufacturing
Slide 22: Specialty Vehicle Manufacturing
Specialty Vehicle Manufacturing Company has engaged JPMorgan Chase to manage a sales process for this division. Estimated value is $100-$115 million
Slide 23: Specialty Vehicle Manufacturing
Specialty Vehicle Manufacturing AK Specialty Vehicles is Global Leader in the Design, Engineering and Construction of Specialty Vehicles. Medical Imaging Broadcast & Communications Command/Homeland Security
Slide 24: Leadership Position in Mobile Medical Worldwide
Leadership Position in Mobile Medical Worldwide Manufacturing Facilities in U.S. and Europe Strategic Relationships for all Modalities GE Healthcare Technologies Philips Medical Systems Siemens Medical Solutions Extraordinary Market Breadth Australia Korea Italy Germany Finland Norway United Kingdom
Slide 25: Leadership Position in Broadcast & Communications Vehicles Worldwide
Leadership Position in Broadcast & Communications Vehicles Worldwide Strong Customer Base Major Networks - ABC, CBS, FOX, NBC Cable Networks - CNN, Time Warner Satellite Uplink Service Market Relay House, PSSI, Calhoun, Arctek, Coastal, STS Export Market Canada, Morocco, Vietnam, Hong Kong Barriers
Slide 26: Homeland Security
Homeland Security Trailer Image
Slide 27: Homeland Security
Homeland Security Market Breadth: Mobile Communications Centers First Responder Units Mobile Emergency Ops Units Military Training Simulators Tactical transport
Slide 28: Homeland Security
Homeland Security Federal Funding Programs $2.6B In Federal Funds are Allocated for 2005: Urban Area Security Initiative Grant Earmarked for Top 50 Metropolitan Areas State Homeland Security Grant States/Municipalities Response Capabilities 2005 Programs Initiated by DOHS Include: National Protectio
Slide 29: Conclusion
Conclusion Market Dominator Hi Barriers to Entry “Debt-Free” Segment Focused, Stand Alone Business Unit
Slide 30: 2006 Financial Forecast
a HealthTronics 2006 FINANCIAL FORECAST HealthTronics
Slide 31: Segment Summary Income Statement 2006 Forecast
Segment Summary Income Statement 2006 Forecast
Slide 32: Key Financial Statistics
Key Financial Statistics (3 in mittions) 2006 Forecast Total Debt Cash Net Debt Ratios: Funded Debt to EBITDA A/R Days Sales Outstanding Interest Coverage (Adjusted EBITDA/interest Expense) Net Working Capital 12/31/06 $75 ao HealthTronics HealthTronics
Slide 33: 2006 Forecast Pro Forma Free-Cash Flow
2006 Forecast Pro Forma Free-Cash Flow
Slide 34: Consolidated Summary Income Statement
Consolidated Summary Income Statement
Slide 35: Implementation of Strategic Initiatives
Implementation of Strategic Iniatives 1. Proceed with FDA approval for HIFU 2. Introduce Urology Imaging System 3. Establish UroPathology Capability (early 2006) 4.Focus on strategic acquisition targets 5.Divest Specialty Vehicles Division
Slide 36: Reconciliation of EBITDA and Adjusted EBITDA
Reconcilitation of EBITDA and Adjusted EBITDA
Slide 37: Reconciliation of EBITDA and Adjusted EBITDA
Reconcilitation of EBITDA and Adjusted EBITDA
Slide 38: EBITDA and Adjusted EBITDA
EBITDA and Adjusted EBITDA HealthTronics has presented EBITDA and Adjusted EBITDA amounts, which are non-GAAP financial measures, in various filings with the SEC. In the SEC filings, HealthTronics has reconciled such amounts to their most directly comparable financial measure calculated in accordanc
Slide 39: EBITDA and Adjusted EBITDA
EBITDA and Adjusted EBITDA EBITDA and Adjusted EBITDA are used in addition to and in conjunction with results presented in accordance with GAAP. EBITDA and Adjusted EBITDA should not be considered as an alternative to net income, operating income, a liquidity measure, or any other operating performa